ArticleCancer biotherapy & radiopharmaceuticals2010
Positive progress in immunoPET--not just a coincidence.
Article in Cancer biotherapy & radiopharmaceuticals, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- ImmunoPET Directed to the Brain: A New Tool for Preclinical and Clinical Neuroscience.Biomolecules · 2023Review
- Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography.Journal of clinical medicine · 2021Review
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
- Tri-functional platform for construction of modular antibody fragments forChemical science · 2020Article
- On-demand radiosynthesis ofRSC advances · 2019Article
- PET Imaging of Receptor Tyrosine Kinases in Cancer.Molecular cancer therapeutics · 2018Review
- Dosimetry Prediction for Clinical Translation ofScientific reports · 2018Article
- Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
- Biodistribution Analyses of a Near-Infrared, Fluorescently Labeled, Bispecific Monoclonal Antibody Using Optical Imaging.Comparative medicine · 2016Article
- The pharmacokinetics of Zr-89 labeled liposomes over extended periods in a murine tumor model.Nuclear medicine and biology · 2015Article
- Applications of in vivo imaging in the evaluation of the pathophysiology of viral and bacterial infections and in development of countermeasures to BSL3/4 pathogens.Molecular imaging and biology · 2015Review
- Immuno-PET imaging of tumor endothelial marker 8 (TEM8).Molecular pharmaceutics · 2014Article
- Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.Molecular pharmaceutics · 2014Article
- Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.Molecular cancer therapeutics · 2014Article
- Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.Biomaterials · 2014Article
- Engineered antibodies for molecular imaging of cancer.Methods (San Diego, Calif.) · 2014Review
- Antibody-based imaging of HER-2: moving into the clinic.Current molecular medicine · 2013Review
- Mapping biological behaviors by application of longer-lived positron emitting radionuclides.Advanced drug delivery reviews · 2013Review
- Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments.Molecular imaging and biology · 2013Article
- Fluorescent affibody peptide penetration in glioma margin is superior to full antibody.PloS one · 2013Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
The identification of tumor tissue biomarkers has led to the production, validation, and Food and Drug Administration-approval of a number of antibody-based targeted therapeutics in the past two decades. As a result of the significant role that these immunotherapeutics play in the management of cancer, and the potential utility of complementary imaging agents, immunoPET imaging has generated considerable interest. This update discusses the important factors to consider when designing a PET (positron emission tomography) imaging agent from the molecular target to the biological targeting molecule and radionuclide combination and also reviews recent preclinical and clinical findings in the immunoPET field. Although there are a variety of radionuclides that are currently utilized in PET studies, this update focuses on four of the positron emitters commonly used in labeling proteins: iodine-124, zirconium-89, copper-64, and fluorine-18. Notable advances in the preclinical setting include the continued development of immunoPET probes to predict the biodistribution of related radioimmunotherapeutics, the success of nontraditional radionuclide and antibody fragment combinations, the broader use of zirconium-89, and the recent emergence of (18)F-labeled diabodies for same-day imaging. Antibody-based PET probes constitute a valuable class of molecular imaging agents, and the progress made preclinically should expedite the transition of these targeted diagnostics to clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.